Clinical trials: Tislelizumab
Esophageal Squamous Cell Carcinoma
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
This is a prospective, single-center, single-arm Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with tislelizumab in patients with advanced esophageal squamous cell…
- Trial name
- NCT07811752
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Shanghai Chest Hospital
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to…
- Trial name
- NCT07812467
- Testing
- Rimegepant, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell…
- Trial name
- NCT05343325
- Testing
- Tislelizumab, Low-dose radiotherapy
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Malignant Solid Tumors
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
- Trial name
- NCT06499350
- Testing
- FC084CSA+Tislelizumab combination (dose escalation), RP2D of FC084CSA+Tislelizumab combination (dose expansion)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic…
- Trial name
- NCT07801352
- Testing
- Capecitabine, Oxaliplatin, Dihydroartemisinin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Breast Cancer, Gastric Cancer
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of zanidatamab in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04276493
- Testing
- Zanidatamab, Docetaxel, Tislelizumab
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 71 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma (HCC)
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
This is an open-label, multicenter, randomized controlled Phase II trial. Patients with advanced hepatocellular carcinoma (HCC) who developed secondary resistance to first-line targeted-immunotherapy were randomly assigned to…
- Trial name
- NCT07463248
- Testing
- Tislelizumab Combined With TKI, Fecal Microbiota Transplantation, PULSAR
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Wang Xin
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT05909904
- Testing
- Tislelizumab, BGB-A425, LBL-007
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 160 people
- Sponsor
- BeiGene
B-cell Malignancies
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study.
- Trial name
- NCT04170283
- Testing
- Zanubrutinib, Tislelizumab
- Where
- 153 sites in United States, Australia and 16 more
- Volunteers
- 955 people
- Sponsor
- BeOne Medicines
Liver Cancer
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Targeted Therapy and a PD-1 Inhibitor in Patients with Postoperative Hepatocellular Carcinoma…
- Trial name
- NCT07790419
- Testing
- HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhai Wenlong
Richter Transformation
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation
- Trial name
- CLL-RT1 (NCT04271956)
- Testing
- Tislelizumab, Zanubrutinib, Sonrotoclax
- Where
- 11 sites in Austria, Denmark and 1 more
- Volunteers
- 83 people
- Sponsor
- German CLL Study Group
Extranodal NK-T-Cell Lymphoma, Early-stage
A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage…
- Conditions
- Extranodal NK-T-Cell Lymphoma, Early-stage, High-Risk Cancer
- Trial name
- CLCG-2102 (NCT05254899)
- Testing
- Anti-PD-1 monoclonal antibody, Pegaspargase, Gemcitabine
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
This is a prospective, single-arm, multicenter phase II clinical study evaluating the efficacy and safety of spatially fractionated radiotherapy (SFRT) combined with tislelizumab and platinum-based doublet chemotherapy as…
- Trial name
- NCT07775040
- Testing
- Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
The goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck…
- Trial name
- NCT07776340
- Testing
- Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Hodgkin Lymphoma
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
This is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.
- Trial name
- FIL_Tisle-HL (NCT05977673)
- Testing
- Tislelizumab
- Where
- 12 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Gastroesophageal Adenocarcinoma
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
ARMANI-2/ENGIC8 is a randomized, open-label, phase III trial evaluating a switch maintenance strategy in patients with previously untreated, locally advanced unresectable or metastatic, HER2-negative and PD-L1-positive…
- Trial name
- ARMANI-2 (NCT07763171)
- Testing
- FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu
- Where
- 42 sites in Germany, Italy and 1 more
- Volunteers
- 244 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Non-small Cell Lung Cancer, Consolidation Immunotherapy
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy.
- Conditions
- Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation
- Trial name
- NCT05758116
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic…
- Trial name
- NCT06416410
- Testing
- JAB-21822, Tislelizumab, JAB-3312
- Where
- 37 sites in China
- Volunteers
- 392 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung…
- Trial name
- NCT06091943
- Testing
- Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet
- Where
- 15 sites in China, Georgia and 1 more
- Volunteers
- 62 people
- Sponsor
- BeiGene